Inhibiting B cell activating factor attenuates preeclamptic symptoms in placental ischemic rats. (27th February 2023) - Herrock, Owen
Abstract: Problem: Preeclampsia (PE), new‐onset hypertension during pregnancy, is associated with a pro‐inflammatory state with activated T cells, cytolytic natural killer (NK) cells, dysregulated complement proteins, and B cells secreting agonistic autoantibodies to the angiotensin II type‐1 receptor (AT1‐AA). The reduced uterine perfusion pressure (RUPP) model of placental ischemia recapitulates these features of PE. Blocking CD40L‐CD40 communication between T and B cells or B cell depletion with Rituximab prevents hypertension and AT1‐AA production in RUPP rats. This suggests that T cell‐dependent B cell activation contributes to the hypertension and AT1‐AA associated with PE. B2 cells maturing into antibody producing plasma cells are the product of T cell‐dependent B cell‐interactions and B cell Activating Factor (BAFF) is an integral cytokine in the development of B2 cells specifically. Thus, we hypothesize that BAFF blockade will selectively deplete B2 cells, therefore reducing blood pressure, AT1‐AA, activated NK Cells, and complement in the RUPP rat model of PE. Method of study: Gestational Day (GD) 14 pregnant rats underwent the RUPP procedure, and a subset were treated with 1 mg/kg Anti‐BAFF antibodies via jugular catheters. On GD19, blood pressure was measured, B cells and NK cells were measured by flow cytometry, AT1‐AA was measured by cardiomyocyte bioassay, and complement activation was measured by ELISA. Results: Anti‐BAFF therapy attenuated hypertension, AT1‐AA, NK cell activation, and APRIL levels in RUPP rats without negatively impacting fetal outcomes. Conclusions: This study demonstrates that B2 cells contribute to hypertension, AT1‐AA, and NK cell activation in response to placental ischemia during pregnancy.